{
    "Trade/Device Name(s)": [
        "Access hsTnI"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K230648",
    "Predicate Device Reference 510(k) Number(s)": [
        "K172787"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "December 4, 2023",
    "Summary Letter Received Date": "October 31, 2023",
    "Submission Date": "March 8, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cardiac troponin I (cTnI)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access 2 Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Sandwich assay"
    ],
    "Methodologies": [
        "Enzyme immunoassay",
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Access hsTnI chemiluminescent immunoassay for cardiac troponin I on the Access 2 Immunoassay Systems",
    "Indications for Use Summary": "Quantitative determination of cardiac troponin I in human serum and plasma to aid in diagnosis of myocardial infarction using Access 2 Immunoassay Systems",
    "fda_folder": "Clinical Chemistry"
}